Results 111 to 120 of about 2,386 (174)

Safe Continuation of Apheresis during Pregnancy using the Double-Filtration Plasmapheresis Thermo Mode in a Pregnant Female with Familial Hypercholesterolemia: A Case Report. [PDF]

J Atheroscler Thromb
Sakurabu Y, Uchida HA, Okuyama Y, Eto E, Takasugi K, Asakawa T, Katayama K, Okamoto S, Onishi Y, Matsuoka-Uchiyama N, Fujihara C, Tanaka K, Takeuchi H, Umebayashi R, Tanabe K, Wada J.   +15 more
europepmc   +1 more source

Lomitapide response in a cohort of patients with homozygous familial hypercholesterolemia and the potential influence of MTTP gene variants. [PDF]

Orphanet J Rare Dis
Kolovou G, Kolovou V, Anagnostopoulou K, Anastasiou G, Kalogeropoulos P, Liberopoulos E.   +5 more
europepmc   +1 more source

Impact of severe dyslipidemia on renal function: A cross-sectional study. [PDF]

Medicine (Baltimore)
Lewandowski N, Reinhardt W, Spitthöver R, Kribben A, Boss K, Mülling N.   +5 more
europepmc   +1 more source

Lipoprotein(a): Role in Cardiovascular Risk and Advances in Novel Therapeutics. [PDF]

Cureus
Murillo Sotela A, Orozco Loaiza G, Villalobos Villalobos P, Alfaro Guerra J.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

State of the Art of Low-density Lipoprotein Apheresis in the Year 2003

Therapeutic Apheresis and Dialysis, 2004
Abstract:  Low‐density lipoprotein (LDL) apheresis is a last‐resort treatment for hypercholesterolemic patients resistant to conservative lipid‐lowering therapy. In the extracorporeal circuit, LDL, Lp(a) and coagulation factors are selectively eliminated, while the beneficial proteins like high‐density lipoprotein, albumin and immunoglobulins are ...
Thomas Bosch
exaly   +3 more sources

Low-Density Lipoprotein Apheresis: Clinical Results with Different Methods

Artificial Organs, 2002
Abstract: In 40 patients (22 women, 18 men) suffering from familial hypercholesterolemia resistant to diet and lipid lowering drugs, low‐density lipoprotein (LDL) apheresis was performed over 84.9 ± 43.2 months. Four different systems (Liposorber, 28 of 40, Kaneka, Osaka, Japan; Therasorb, 6 of 40, Baxter, Munich, Germany; Lipopak, 2 of 40, Pocard ...
Rolf Bambauer
exaly   +3 more sources

Low‐density Lipoprotein Apheresis: An Overview

Therapeutic Apheresis and Dialysis, 2003
Abstract:  Atherosclerosis with myocardial infarction, stroke, and peripheral cellular disease still maintains its position at the top of morbidity and mortality statistics in industrialized nations. Established risk factors widely accepted are smoking, arterial hypertension, diabetes mellitus, and central obesity.
Rolf, Bambauer, Ralf, Schiel, Reinhard, Latza   +2 more
openaire   +2 more sources

Indications for low-density lipoprotein apheresis

The American Journal of Cardiology, 1994
Low-density lipoprotein (LDL) apheresis offers an additional approach to lipid lowering in patients with severe hypercholesterolemia who fail to respond adequately to diet and drug therapy. Well-defined criteria for patient selection have yet to be established for LDL apheresis.
B R, Gordon, E, Stein, P, Jones, D R, Illingworth   +3 more
openaire   +2 more sources

Current Topics on Low-Density Lipoprotein Apheresis

Therapeutic Apheresis and Dialysis, 2001
The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) (Lp[a]) levels, and coronary heart disease (CHD) refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density lipoprotein (LDL) apheresis is the therapeutic option.
R, Bambauer, R, Schiel, R, Latza
openaire   +2 more sources